Insight Molecular Diagnostics Inc. — Director's Dealing 2025

Feb 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2025-02-07

Reporting Person: James Andrea S. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-07	Common Stock, no par value	P	97561	$2.05	Acquired	151231	Direct

Footnotes

F1: Reflects shares of the Issuer's common stock, no par value, purchased by the Reporting Person from the Issuer in a private placement pursuant to that certain Securities Purchase Agreement, dated as of February 7, 2025, by and among the Issuer and the investors signatory thereto.